Outcome of Radioiodine Treatment by Using 4-Hour l-131 Uptake Value for Dose Calculation in Graves’ Disease
Keywords:
Hyperthyroidism, Early |-131 uptakeAbstract
Objective: To evaluate outcome of radioiodine treatment by using 4-hour 131I uptake value for calculation therapeutic dose for patients with Graves’disease.
Materials and Methods: We studied 122 Graves’ disease patients with hyperthyroidism. The 4-hour 131I uptake was done in each patient. the 24- hour 131I uptake was estimated from the equation: predicted 24 hr 131I uptake = 36.7764 + 0.518 (4 hr 131I uptake). The RAI treatment dose was calculated using the formula based on estimated thyroid size and predicted 24-hour 131I uptake. We determined thyroid status of these patients at 1 year after the treatment.
Results: Ninety - five patients (77.9%) were euthyroidism or hypothyroidism at 1 year after treatment. and Twenty-seven patients (21.1%) had persistent hyperthyroidism. The patients who had persistent hyperthyroidism had larger thyroid gland (P < 0.001) and higher 4- hr 131I uptake value (P = 0.003). We found the outcome of treatment of our study were similar to the outcome of other studies that used other regimens in the treatment of Graves’ disease patients with 131I.
Conclusion: Radioiodine treatment (“*l) based on 4- hour 131I uptake is an effective treatment for patients with Graves’ disease. This approach is safe, simple and convenience for the patients.
Downloads
Metrics
References
Sawin CT. Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid 1997:7 163-76
Soloman B. Glinoer D. Lagasse R. Wartofsky LN. Current trends on the management of Graves’ disease. J Clin Endocrinal Metab 1990:70:1518-24
Dietlein M, Lauterbach KW. Schicha H. Treatment of toxic nodular goiters: comparative costing of radioiodine therapy and surgery. Exp Clin Endocrinol Diabetes 1998:106 (Supp! 4):S66-S70.
Franklyn JA. Daykin J. Drole Z. Farmer M. Sheppard MLN Long term follow up of treatment of thyrotoxicosis by three different methods. Clin Endocrind (Qxf) 1991:34:71-6.
Hayes AA. Akre CM. Garman CA . lodine - 131 treatment of Graves’ disease using modified early iodine-131 uptake measurement in therapy dose calculation. J Nucl Med 1990:31:519-22.
Hennessey JV. Berg LA, Ibrahim MA. et al . Evaluation of early (5 to 6 hours) lodine - 123 uptake for diagnosis and treatment planning in Graves’ disease. Arch Intern Med 1995:155:621-24
Usha SV. Francis BA. Harvey AZ. Therapy dose calculation in Graves’ disease using early I-123 uptake measurements. Clin Nucl Med 1996:21:102-05
Kingpetch K. Poshyachinda M. Dose calculation using 4-hour I-131 uptake for retreatment radioiodine therapy of patients with Graves’ disease Asean J Radio 2003:9: 63-8.
Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years?. J Nuc! Med 1993:34:1638-41
Alexander EK. Larsen PR. High dose 131l therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinal Metab 2002:87:1073-77
Leslie WD, Peterdy AE . Dupont JO. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves’ hyperthyroidism. J Nucl Med 1998:39:712-6.
Solomon B. Glinoer D. Lagasse R. Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1989:70:1518-22
Sawers JS, Toft AD. Irvine WJ. Brown NS. Seth JN . Transient hypothyroidism after iodine - 131 treatment of thyrotoxicosis. J Clin Endocrinal Metab 1980:50:226-9.
Aizawa Y, Yoshida K. Kaise N. Fukazawa H. Kiso Y. Sayama N. Hori H. Abe K. The development of transient hypo thyroidism after iodine - 131 treatment in hyperthyroid patients with Graves’ disease prevalence. mechanism and prognosis. Clin Endocrinal (Oxf) 1997:46:1-5
Gomez N, Gomez JM. Orti A. Gavaida L. Villabona C. Leyes P. Soler J. Transient hyothyroidism after iodine - 131 therapy for Graves’ disease. J Nucl Med 1995:36: 1539-42.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)